INCREASED REPORTING OF ADVERSE DRUG REACTIONS TO ANTI-TB MEDICATION AFTER IMPLEMENTATION OF PAVIA PROJECT IN TANZANIA

Kissa W. Mwamwitwa, Marion Sumari-de Boer, Hadija Semvua, Eva Muro, Seth H. Kisenge, Nellin Shiletiwa, Alex Nkayamba, Adam M. Fimbo, Blandina T. Mmbaga

Introduction

☐ Post-marketing monitoring of adverse drug reaction (ADRs) is still limited.

☐ In 2018, the PAVIA (Pharmacovigilance Africa) Project started.

☐ It aimed to strengthen PV focused on multi-drug resistant (MDR) TB.
☐ The objective of this study was to investigate trends in reporting of ADR for anti-TB before and during PAVIA.

Methods

❖ Explored trends in ADR-reports using data from Vigiflow,

❖ a web-based individual case safety report (ICSR) management system

❖ The PAVIA project implemented blended e-learning on reporting of ADR.

❖ The number of reported ADRs including anti-tuberculosis ADRs were collected form 2014 to April 2021.

❖ We analyzed frequencies of ADR-reports for all drugs including anti-TB-drugs

Results

➢ Total number of ADR reported was 21,747 since 2014 to April 2021 of which 561 (2.1%) were related to anti-TB medication.
➢ In 2015, reports were 276 with 10 (4%) anti-TB-medication related.
➢ In the first year of PAVIA (2018), the number of reports increased to 1,363 with 199 (15%) anti-TB-medication related
➢ It increased in 2nd Year to 15,024 with 133 (1%) anti-TB-medication related.
➢ Overall, ADR-reports for anti-TB-medication during PAVIA (2019-2021) 431/19933 (2%).

Discussion

The study indicated the overall increase of ADRs reports, including ADRs for Anti TB medications, however they contributed less to the total number of ADRs

Conclusion: Since implementation of PAVIA, a clear increase in the trend of total reported ADR including for Anti-TB drugs has been shown. As Tanzania has implemented other programmes, and though ADRs for Anti-TB increased, the actual effect of PAVIA should be further investigated

Extra Tables & Figures

ADR reporting in Tanzania

■ Total ADR ■ Anti-TB ADR